MarketInOut Stock Screener Log In | Sign Up
 

Corcept Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 07/02/2026 16:00
Corcept Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9,435.13 mln
Float89.94 mln
Earnings Date08/05/2026

EPS

0.35
Overpriced

P / E

258
Bubble territory

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-3.3
Reliable

1-Year Forecast

88.00
Fairly priced

Relative Strength

86 / 100
Strongly outperforming

Business Description

Corcept Therapeutics is a US-based pharmaceutical company focused on developing drugs that target the effects of cortisol, a hormone that can cause serious harm when the body produces too much of it. Its main product, Korlym, is an approved oral treatment for adults with Cushing's syndrome whose excess cortisol has led to blood sugar problems and who cannot or did not benefit from surgery. The company also has several additional compounds in various stages of clinical testing, targeting conditions such as liver disease and ALS. Founded in 1998 and based in Redwood City, California, Corcept has built its entire business around understanding and controlling cortisol's role in disease.

Key Fundamentals

EPS0.35
P/E258
ROE7.31
RPS6.61
ROIC-1.86
ROA5.74
EBITDA, mln-6.19
EV / EBITDA-1,460
EV / EBIT-1,100
Revenue, mln769
EV / Revenue11.76

Financial Strength

Altman Z-Score34.25
Piotroski F-Score 4 / 9
Beneish M-Score-3.3
Price to Intrinsic Value3.50
Price to Graham Number12.85
1-Year Target Price88.00
Shiller PE Ratio94.80
Short Ratio8.55
Short % of Float10.31

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 6.44% 81 / 100   
1 Month 26.7% 95 / 100   
2 Months 123% 98 / 100   
6 Months 28.52% 85 / 100   
1 Year 30.15% 76 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us